Cellular immunotherapy firm Bellicum Pharmaceuticals Inc. landed $55 million in an oversubscribed series C less than eight months after closing its $34.4 million B round, raising the company's total haul to $107 million since launching in 2004. Read More
With its inhaled levodopa product for Parkinson's disease (PD) gearing up for a phase III trial and $55 million just gained in a series C financing, Civitas Therapeutics Inc. filed to raise up to $86.2 million in an initial public offering (IPO). Read More
BOGOTA, Colombia – A community in Colombia is increasingly afraid of a human papillomavirus (HPV) vaccine after about 100 girls started showing a range of symptoms from headaches to fainting and numbness. Read More
"Recalling a memory is not like playing a tape recorder," Susumu Tonegawa told reporters. "It is a creative process." Normally, that creativity comes from the organism – man or mouse – doing the remembering. But Tonegawa, who is at the Massachusetts Institute of Technology, and his colleagues have managed to be creative with mouse memories, by altering the association between so-called episodic memories and the emotions that accompanied them. Read More
Biothera Inc., of Eagan, Minn., said the NIH awarded a Small Business Innovation Research grant for the continued development of a fungal vaccine. Read More
Asterias Biotherapeutics Inc., of Menlo Park, Calif., was cleared by the FDA to begin a phase I/IIa trial of its cell therapy, AST-OPC1, in patients with complete cervical spinal cord injury. Read More
Bristol-Myers Squibb Co., of New York, said the European Commission approved Daklinza (daclatasvir), a pan-genotypic NS5A replication complex inhibitor, for use in combination with other products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults. Read More
